Pheromones, sexual attractiveness and quality of life in menopausal women

W. B. Cutler and E. Genovese*

Athena Institute for Women’s Wellness, Chester Springs, Pennsylvania; *IMX Medical Management Consultants, Bala Cynwyd and University of Pennsylvania School of Medicine, USA

Key words: SEXUAL ATTRACTION, PHEROMONES, MENOPAUSE, HYSTERECTOMY, SEXUAL DYSFUNCTION, MALE AND FEMALE, QUALITY OF LIFE, OLFATORY SYSTEMS

ABSTRACT

Pheromones, and their effects, are reviewed with a special emphasis on their potential contribution to sexual attractiveness in the menopause. Key topics included are biological functions of pheromones in animals and humans, the source of pheromones in humans, the axillary extract studies that led to the independent synthesis of pheromones, olfactory mechanisms for mediating pheromones, and aging, attractiveness and sexual dysfunction.

Physical attractiveness is important for a better quality of life. Three separate, double-blind, placebo-controlled investigations, using the same protocol, all demonstrated that a synthesized pheromone, topically applied, increased sexual attractiveness. If partners are available, sexual attractiveness can increase affectionate intimate behavior, which, in turn, increases well-being and quality of life. More research is needed to address ways in which postmenopausal women can benefit from pheromones.

INTRODUCTION

In nature, sex pheromones are powerful agents driving reproduction and perpetuation of the species. Pheromones, and their effects, have been studied, although not extensively, in postmenopausal women.

The term ‘pheromone’ was first suggested in 1959 by biologists1 exploring a new observation: substances that had the chemical make-up of hormones, but which were excreted, elicited some behavior or developmental response from another individual of the same species. A considerable body of research has now confirmed that pheromones serve the reproductive life of species and are generally species-specific. Hence, the sex attractant pheromone of the wild boar is not an effective sex attractant for humans2.

BIOLOGICAL FUNCTIONS OF PHEROMONES

In humans, four behavioral classes of pheromones have been identified: opposite-sex attractants, male territorial markers or repellents that drive away sexual competitors, substances from babies also found in breast milk that facilitate the mother–infant bond, and male and female underarm essences involved in maintaining fertility and synchronization of menstrual cycles3–5.

We accept without question that consensual affectionate behavior enhances well-being. While secreted hormones serve to maintain the self, excreted pheromones facilitate relationships with others3–4. Hormone replacement therapy enhances hormone-dependent, sexually responsive functions such as sexual motivation, arousal

Correspondence: Dr W. B. Cutler, Athena Institute for Women’s Wellness, Chester Springs, PA 19425, USA

Received 19–10–01
Revised 04–01–02
Accepted 10–01–02
Sex pheromones and orgasmic capacity. Synthesized pheromones may enhance the well-being of menopausal women by increasing their frequency of hugging, kissing and affectionate contact with men.

The natural excretion of pheromones appears to be dependent on the fertile cycle of sex hormone production and to diminish with the decline in fertility, whether natural or surgically induced. The pioneering work with rhesus monkeys of psychiatrist Richard Michael, at Emory University, presents an unambiguous example. His group observed that ovarioctomized rhesus monkeys were unable to attract sexual attention from males, despite actively soliciting through characteristic behavioral displays in which they presented their attractive rear ends. In 1971, Michael and co-workers showed that vaginal smears from intact, sexually attractive, soliciting females could be placed on the rear-ends of post-ovarioctomized females to restore their capacity to attract male sexual attention. He recognized that the substances had a ‘pheromonal’ action and named them ‘copulins’. Subsequently, these monkey sex-attractants were tested in humans by smearing them nightly on the chests of married women, but without the anticipated positive results. Species-specificity may explain this failure.

From 1975 to 1986, Cutler and her colleagues at the University of Pennsylvania performed a series of experiments in several hundred reproductive-aged women, investigating relationships between patterns of sexual behavior and fertility. For at least 14 consecutive weeks, women recorded the occurrence of sexual behavior and menstrual onsets daily. Some studies also included daily basal body temperature records, and blood samples for sex hormone assay. Subsequently, at Stanford University, similar data were gathered in 124 menstruating perimenopausal women. In composite, the studies showed that, compared with less sexually active women, those who engaged in at least one intimate heterosexual behavior per week also exhibited the following characteristics: more fertile basal body temperature pattern, more normal menstrual cycle length (29.5 days), substantially higher levels of estrogen and, in the menopausal transition years, later onset of menopause and significantly lower incidence of hot flushes. Sporadic sexual behavior (feast and famine) was associated with more deleterious effects than abstinence, more aberrant cycles and the lowest levels of estrogen. Sexual behavior during the week of menses was not necessary for these effects and was later found to be associated with increased risks for endometriosis and excessive menstrual bleeding.

As other replicated aspects of these findings, it became clear that regular intimate exposure to a man, whether through intercourse or genital stimulation in the presence of a man, was associated with positive health benefits. Solitary masturbation was not. This distinction led Cutler and her colleagues to search for a human pheromone, investigating what a man provided for a woman that she could not provide for herself. Studies in animals suggested that sexual partner choice was mediated through pheromonal attraction, but, at that time, no such work had been published relating to humans. However, one intriguing study reported in 1980 that sweat from one woman’s underarm, rubbed on another’s upper lip three times a week for 4 months, caused the recipient’s menstrual cycle to synchronize with the donor’s cycle. Subsequently, this donor’s sweat was further tested on five other recipients in a placebo-controlled, but not blind, trial with similar statistically significant results.

**SOURCE OF PHEROMONES IN HUMANS: AXILLARY EXTRACT STUDIES**

In 1986, the first human, double-blind, placebo-controlled experiments provided strong support for the existence of an axillary source of pheromones in humans. Reproductive-aged men and women in ongoing, heterosexual relationships provided their underarm sweat, which was collected on sterile donor pads and, later, extracted, pooled and frozen. A year later, when these fluids were thawed and filtered to remove the odor and bacteria, an odorless clear fluid provided the first test substances, or ‘essences’, from humans. Two double-blind, placebo-controlled experiments with these substances demonstrated clear pheromonal effects. Women with aberrantly long or short cycle lengths received either the male essence or placebo. Pooled male essences, applied three times per week for 14 weeks to the skin under the nose on the women’s upper lips, caused their menstrual cycle lengths to shift from aberrant to presumptively fertile (29.5-day) cycle lengths. The aberrant cycles of women using placebo stayed aberrantly long or short. Hence, the male essence mimicked the behavioral effect of regular intimate exposure to a male,
generating more presumptively fertile cycle lengths in women.

At the same time, women with presumptively fertile cycle lengths at baseline received either female essence or placebo. Female extracts from elite donors had been pooled by day of cycle to create a pooled day-1, a pooled day-3, a pooled day-5 extract and so on. These odorless substances were applied in sequence to the upper lip of naive women, three times per week, for 14 weeks. The sequential female essence, but not the placebo, produced a shift in onset of the recipients’ cycles that synchronized with the timing of the donor essences. Thus, the applied elite female essence mimicked the behavioral effect that is now recognized; women in close contact with one another tend to cycle together. In 1998, investigators at the University of Chicago further examined the effects of female underarm essences on menstrual timing. They concluded that daily application of pooled preovulatory essences shortened the follicular phase, advancing the onset of ovulation, while pooled postovulatory essences delayed ovulation. Although these effects were small, shifting ovulation time by an average of 1.7 days, they affected 68% of test subjects.

The sexual-attractant effects of odorless extracts of the underarm were also studied. In 1987, Cutler reported that essences of sexually active, presumptively fertile women, when applied three times per week to the upper lip, increased the likelihood that recipients would engage in sexual intercourse at least once a week. Placebo had no effect. At the time, two possible mechanisms were considered: first, that pheromones increase sexual attractiveness of the wearer; or, second, that pheromones cause an increased willingness or receptivity towards men’s sexual advances in these women of reproductive age.

In 1995, Wedekind and colleagues provided additional support for the role of an axillary source of human pheromones in attraction. Young women were asked to score the pleasantness of used T-shirts of men in their mid-20s, most alike and most different from their own major histocompatibility complex (MHC). The researchers reported that sweaty T-shirts were more attractive to women of different, rather than of similar, genetic make-up, as reflected by their MHC. Two years later, these authors confirmed the findings in both men and women. These Wedekind studies provided further evidence that the underarm is an important site for sexual selection, and that genetic variations among individu-


duals may serve to promote genetic variability in the immune systems of their offspring, perhaps to enhance the survival of the parent’s genes.

**SYNTHESIS OF PHEROMONES**

Between 1986 and 1994, Cutler worked at the Athena Institute to synthesize two effective human sex-attractant pheromone formulas. With Dr Norma McCoy at San Francisco State University and Dr Erika Friedmann at Brooklyn College, she developed a rigorous, double-blind, placebo-controlled protocol to test the formulas. In 1994, in Philadelphia, 38 clean-shaven, heterosexual men completed the first double-blind experiment to test whether this putative male synthesized sex-attractant pheromone added to their preferred aftershave would ‘increase the romance in their lives’. Each man completed a daily checklist recording the occurrence of six behaviors that had occurred the day before, and faxed the calendar to the researchers each week. Results are given in Table 1, left column. Within 6 weeks of regular use, a significantly higher proportion of pheromone than placebo users recorded increases over their average weekly baseline behaviors, in the average weekly frequencies of sexual intercourse and sleeping next to a romantic partner. Borderline effects were found for increases over baseline in average weekly frequencies of petting/affection/kissing and informal dates (Table 1). No difference occurred in average weekly frequency of masturbation, suggesting that these pheromones increased the sexual attractiveness of men to women rather than the sexual motivation of the wearer. Overall, 74% of the men who used the pheromone experienced an increase in at least one sociosexual behavior, an effect significantly higher than the 38% of placebo users who did so (p < 0.01).

Professor Norma McCoy and Lisa Pitino tested the women’s formula independently in 2000 in San Francisco. They conducted a double-blind, placebo-controlled trial with 36 commuting university coeds, with a mean age of 27.8 years (range 19–48 years), who were not cohabiting or using an oral contraceptive. Data were collected over three consecutive menstrual cycles. As in the men’s study, the women recorded sexual behavior during a 2-week baseline. Afterwards, they blindly selected placebo or the synthesized pheromone, added the vial to their own preferred perfume and then continued recording daily, with weekly dispatch of their records. In order to provide six non-menstruating experimental weeks, the
Table 1  Summary of experimental results from three double-blind, placebo-controlled trials: heterosexual men and women entered study to test pheromone or placebo in their preferred fragrance, comparing sexual behaviors during 2-week baseline and 6-week experimental periods, recording occurrence of behavior as average number of days per week.

<table>
<thead>
<tr>
<th>Sociosexual behavior</th>
<th>Pheromone</th>
<th>Placebo</th>
<th>Pheromone</th>
<th>Placebo</th>
<th>Pheromone</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Petting, kissing, affection</td>
<td>41</td>
<td>14*</td>
<td>58</td>
<td>24**</td>
<td>41</td>
<td>14***</td>
</tr>
<tr>
<td>Sleeping next to a romantic partner</td>
<td>35</td>
<td>5***</td>
<td>58</td>
<td>18***</td>
<td>18</td>
<td>18</td>
</tr>
<tr>
<td>Sexual intercourse</td>
<td>47</td>
<td>10†</td>
<td>47</td>
<td>6‡</td>
<td>32</td>
<td>27</td>
</tr>
<tr>
<td>Formal dates</td>
<td>41</td>
<td>33</td>
<td>53</td>
<td>18**</td>
<td>32</td>
<td>18</td>
</tr>
<tr>
<td>Informal dates</td>
<td>35</td>
<td>10*</td>
<td>47</td>
<td>47</td>
<td>32</td>
<td>36</td>
</tr>
</tbody>
</table>

*p < 0.07, **p < 0.05, ***p < 0.02, †p < 0.01, ‡p < 0.006, compared with pheromone users

Philadelphia men\(^a\): mean age 33.4 years (range 26–42 years); married \(n = 9\), non-cohabiting \(n = 26\), with steady company \(n = 3\)

San Francisco women\(^b\): mean age 27.8 years (range 19–48 years); non-cohabiting \(n = 36\)

Boston women\(^c\): mean age 56.9 years (range 47–75 years); married \(n = 11\), cohabiting \(n = 1\), non-cohabiting \(n = 32\)

Subjects provided daily data each week for three consecutive menstrual cycles. Data were analyzed, as in the men's study, to provide a non-menstruating 2-week baseline and 6-week experimental period. Results revealed that a significantly higher proportion of pheromone than placebo users reported increases over their average weekly baseline behaviors in the frequencies of the four intimate sociosexual items recorded: sexual intercourse, sleeping next to a romantic partner, petting/affection/kissing, and formal, pre-scheduled, dates (Table 1, middle column). No significant effect of pheromones was revealed for the two non-intimate sociosexual behaviors recorded: male approaches and informal dates, or for solitary sexual behavior, masturbation. Overall, 74% of the women who used the pheromone experienced an increase in at least three sociosexual behaviors, an effect significantly higher than the 24% of placebo users who did so \((p < 0.01)\).

While the San Francisco study was under way, Dr Susan Rako, a Massachusetts psychiatrist and author specializing in sexuality issues in postmenopausal women, initiated an independent pheromone study. The Boston Postmenopausal Pheromonal Study investigated 44 intact (no hysterectomy or ovariotomy) postmenopausal women (mean age 56.9 years) for a 2-week baseline and 6-week experimental period of daily recording of behavior. Twenty-two women tested the synthesized pheromone and 22 others tested the placebo. Co-authoring with Dr Joan Friebely, a researcher at Harvard Medical School in the Psychiatry Department, Rako used the same behavioral questions and protocol as used in the San Francisco and Philadelphia studies. Focusing on the four intimate sociosexual behaviors that were increased in reproductive-aged women who used pheromone\(^d\), the Boston researchers found that 68% of the postmenopausal women who used pheromones experienced an increase in at least one behavior, an effect significantly higher than the 41% of placebo users who did so \((p = 0.03)\). Within specific behaviors, a significantly higher proportion of pheromone than placebo users increased over their baseline behaviors in average weekly frequency of petting/affection and kissing\(^e\). However, the other sociosexual behaviors did not significantly increase (Table 1). Results in the menopausal group appear to be more modest than the results for men and women in their fertile years. Several explanations are possible. There is some evidence\(^f\) that with increasing postmenopausal age, there is a decreasing interest in sexual intercourse. Moreover, in contrast with younger women, there is a reduced availability of male sexual partners for postmenopausal women. In fact, partner status at baseline \((p = 0.01)\) as well as pheromone use \((p = 0.03)\) were the two independent variables that significantly increased the likelihood that
Sex pheromones would increase at least one intimate behavior during the 6-week experimental period. Postmenopausal women may require a longer experimental period, particularly if they need to find a partner, to bring about increases in more intimate sexual behaviors.

**OLFATORY MECHANISMS FOR MEDIATING PHEROMONES**

Physiological mechanisms by which pheromones exert their demonstrated effects are poorly understood. Even in fungi, such as yeast, understanding of the mechanism of action is extremely limited, despite the identification of some interesting chemotactic mechanisms.

In humans, pheromones appear to work through the olfactory system, and without conscious awareness. They appear to be odorless. No discrete effects of scents on any behavioral change related to pheromones have been confirmed. For example, one study examined physiological responses to erotic films, with subjects simultaneously exposed to different fragrances; another studied men and women who were blindfolded, and presented with scented strips of various substances, including hormones and control odors. In both studies, only trivial and short-lived perceptual effects were obtained. Young women at mid-cycle who sniffed androsténol recorded a transient suppression in aggressive mood, compared with those who sniffed placebo. A reduction in deterioration of mood during tedious experiments while sniffing androgens and estrogens was also reported. Circulating androgens are positively correlated with mood and sexual desire in abnormally suppressed states during oral contraceptive use. Such hormone-related mood and sexual motivation changes do not logically qualify as evidence of classical pheromonal effects. Anomalous individuals have also been evaluated, to test the assumption that normal ability to perceive scent might be essential for an adequate sex life. No sexual deficits were identified. Hence, the absence of perception to known aromas, and the presence of responses to odorless substances, suggest that pheromones exert their effects independently of fragrance or other odors.

Gender differences in olfactory self-recognition exist; women have greater acuity. For example, 59% of women but only 6% of men were able to recognize their own underarm odors from samples presented in blinded fashion. It is doubtful that this gender difference in perception would affect the capacity to respond to sex attractants, since the effective underarm essences and the synthesized pheromone formulas used in the six studies discussed above were odorless.

Two anatomical olfactory sites in the nose are candidates for pheromonal receptivity. One is the olfactory epithelium, which carries neural impulses to the main olfactory bulb (MOB), en route to cortical regions of the brain. The other is the vomeronasal organ (VNO), which carries impulses to the accessory olfactory bulb (AOB), en route to subcortical regions of the brain. The human VNO grows during gestation, and is found as a bilateral structure in all normal adult noses. Hormones mechanically pumped into the VNO inhibit gonadotropin releasing hormone and testosterone, and provoke transient decreases in cardiac rate and respiratory frequency. Sniffing such compounds activates the hypothalamic and ventromedial nuclei. Such drug-like, mood-related effects are not classical pheromonal effects.

The MOB bypasses the VNO without any apparent communication. This is shown in mammalian maternal learning of an infant's odor, and infant recognition of its mother in triggering the suckling reflex. Stimulus access is via olfactory receptors, and the MOB has widespread projections to the neocortical processing areas of the brain, in contrast with the AOB, which only projects subcortically. VNO destruction does not disrupt the maternal pheromonal behavior, suggesting that the neurophysiological connection is maintained solely via the main olfactory system.

According to Brennan and Keverne's comprehensive review, in a variety of animals the two systems have evolved separately to fulfill very different functions. The main olfactory system is able to make fine discriminations among an enormous variety of odor molecules, changing their associative values, and linking them to different behavioral outputs. In contrast, the accessory system (VNO) is highly specialized for the detection of a limited range of chemical messages, specific to a species, linked to relatively stereotyped behavioral and neuroendocrine outputs. Moreover, in a recent investigation of the controversial claims for VNO involvement in mood changes when hormones were sniffed, investigators concluded that the VNO appeared neither necessary nor a sufficient pathway for these effects. In 2000, a putative pheromone receptor gene expressed in human olfactory mucosa was reported for the first time, establishing the first experimental basis for our
Sex pheromones

deduction that sex-attractant pheromones are mediated in the olfactory epithelium.

INTENSITY

There is some evidence that more intense concentrations of pheromones become increasingly un-attractive. This may be due to saturability of receptors or to some other, as yet unexplored, mechanism. At low doses, the effect of the combination of two bacterial pheromones on human neutrophils was additive for chemoattractiveness. At higher doses the effects were not seen, suggesting that, once receptors are saturated, increasing the quantity does not increase the effectiveness.

AGING AND ATTRACTION?

WILL PHEROMONES ENHANCE QUALITY OF LIFE IN MENOPAUSAL YEARS?

Physical attractiveness is important for a better quality of life. In young women, the perception that one is physically attractive appears to be important in positive sexual adjustment. Perlini and colleagues demonstrated that younger and older judges of computer-altered photos exhibited a clear attractiveness bias, which can be accurately described as: 'What is beautiful is also more socially desirable and good'. Being judged attractive in the older years will lead to perceptions by others that one is a better person than if one is not judged attractive. Some evidence for a sex bias also exists in that older women are likely to perceive themselves as less attractive than they perceive older men. Our Medline literature search yielded no references to sexual attractiveness in the menopause. A relative variation across cultures is documented in symptoms at menopause, and their attribution to hormonal changes, fertility-role changes, femininity, and status changes, but the importance of 'sexual attractiveness' remains unstudied, although widely appreciated. Sexual attractiveness is the ubiquitous life-blood of pop culture. In the USA, there is unanimity of public opinion, as expressed in the media, that the more fertile-appearing the female is, the more sexually attractive she is. Sex-attractant pheromones may have the capacity to restore the subtle chemistry of this equation, much as hormone replacement therapy helps to stem the tide of other menopausal declines.

Theoretically, five factors determine the sexual attractiveness of a woman:

1. Physical appearance and grooming;
2. Social skills – flirting, bodily grace, confidence;
3. Sexual motivation and interest in romantic contact and lovemaking;
4. Sexual skills;
5. Excretion of sex-attractant pheromones.

Menopausal declines occur in the physical, the motivational and the pheromonal components. Because topically applied pheromones increase hugging, petting and affectionate contact with men, they have the potential to improve the quality of life for postmenopausal women who are experiencing a decline in attractiveness related to aging.

Sexual changes with age and hormonal diminution are well defined. The McCoy Female Sexuality Questionnaire (MFSQ) was developed to assess those aspects of feminine sexuality likely to be affected by declines in sex hormones. The MFSQ has been used in seven recent studies, and all show decreases in item ratings on sexuality as women progress through the menopausal transition, and these ratings correlate with endocrine state. McCoy concluded that 'no good evidence exists on the effect of menopause on sexual attractiveness; but the obvious hypothesis based on a literature review is that the effect is a negative one'. In her view, 'a better understanding of attractiveness or 'sexiness' in non-cycling women, including the role of pheromones, would undoubtedly shed further light on this issue'.

Perception counts. Studies of sexual arousal graphically measuring blood flow to the genitals reveal that blood flow contributes less to a woman's assessment of her own sexual excitement than does the woman's perception of her sexual arousal. Hence, perception appears to be more critical than objective scores. Similar findings in aging men by Davidson and colleagues (cited in reference 11) affirm the importance of perception in the evaluation of patient needs. Women's satisfaction with their sexual relationships was also more closely associated with their marital adjustment, and bore no relationship to age, in an Oxford University study of 436 women.

Sexual behavior changes as women progress from pre- to postmenopause. Findings show that the frequency of sexual intercourse and orgasm declines in postmenopausal women. One of the most comprehensive studies of women's sexuality, by Dennerstein and her colleagues, evaluated 428 Australian-born women aged 45–55 years at
baseline, with six annual assessments in the women's homes using selected questions from the MFISQ. They reported that menopausal status had direct effects on 'feelings for her partner' and the partner's sexual problems. Recently, investigators have moved towards developing a menopause-specific 'quality-of-life' questionnaire. A change in sexual desire, vaginal dryness during intercourse and avoidance of intimacy were each shown to be relevant to the 'quality of life'. Compared with the premenopausal years, 481 women in their postmenopausal years had a 10.6-fold higher risk for vasomotor problems, a 5.7-fold higher risk for physical impairments, a 3.5-fold higher risk for psychosocial impairments and a 3.2-fold higher risk for sexual impairments. 'Being sexually active' was a protective factor against impairment in either physical or psychosocial conditions. While the role of sexual attractiveness in promoting or maintaining sexual activity was not evaluated in any of the studies, such a role would seem likely. If partners are available, sexually attractive women can be expected to be more sexually active than women who are not sexually attractive.

POTENTIAL FOR PHEROMONAL USE IN SEXUAL DYSFUNCTION AND AFTER Hysterectomy

Controversy exists in the literature about the impact of hysterectomy on the sex life of women. Several studies have concluded that 1 and 2 years after hysterectomy, compared with 30 days before scheduled hysterectomy, sex life has improved, for example in the frequency of intercourse. Recently, we have challenged these conclusions, arguing that the seeming improvements shown are biased by the choice of a baseline immediately preceding hysterectomy. Choosing the sexual nadir in the lives of women awaiting hysterectomies, and showing improvement 2 years later, does not demonstrate that it was hysterectomy that improved sex life. Rather, the reverse is supported by recent studies; sex life is suppressed when hysterectomy is scheduled. Shifren and colleagues estimated that 29% of post-hysterectomized women may suffer from sexual dysfunction; this conclusion was based on a survey inviting all patients whose surgery had occurred more than 1 year, but less than 6 years, earlier to participate in a 15-visit evaluation of sexual deficits.

Research into female sexual dysfunction, like research into healthy female sexuality, has not yet incorporated an investigative vocabulary about attractiveness, despite a seminal paper on the critical role of attractiveness in female sexuality published in 1976. For example, in 1999, Berman and co-workers reviewed the sexual dysfunction literature and the treatment options without ever mentioning sexual attractiveness. Heiman and Meston reviewed the Diagnostic and Statistical Manual of Mental Disorders (DSM IV) listing of sexual dysfunction standards, which also omitted any reference to sexual attractiveness. It is possible that the almost ubiquitous decline in sexual interest after the menopause is related to the decline in sexual attractiveness.

The evidence seems to suggest that pheromonal output varies among individuals, and is highest during peak reproductive times such as at ovulation and during the fertile years. Output diminishes with the loss of reproductive fertility. In the rhesus monkey, surgically induced loss of the reproductive hormones via ovariectomy and hysterectomy abolishes the natural secretion of sex-attractant pheromones. Attractiveness can be restored with the topical application of the species-specific pheromone, or by replacing the missing reproductive hormones appropriately. In women, there is a suggestion that, after hysterectomy, a loss of sexual attractiveness may be commonly experienced. Scholars at the University of Oklahoma independently purchased and began testing the pheromone formula in postmenopausal women taking hormone replacement therapy who complained of a loss of attractiveness. They reported anecdotally — from their uncontrolled experiment — that about 70% of post-hysterectomized women using the topical pheromone formula described increased sexual activity within several weeks of regular use. Professor Clark Bundren terminated their study, and recommended that patients simply use the pheromone product. There is a need for a double-blind, placebo-controlled study.

THE FUTURE

Three separate, double-blind, placebo-controlled investigations, using the same protocol, all demonstrated that a synthesized pheromone, topically applied, increased sexual attractiveness. If partners are available, sexual attractiveness can increase affectionate intimate behavior, which, in turn, increases well-being and quality of life. In fact, regular sexual behavior is associated with physiological health. Hence, in the future,
physicians interested in fostering physical, psychological and sexual health in their aging patients may not only optimize function by prescribing sex hormones; they might also attempt to ensure that couples maintain their attractiveness to each other through the use of pheromones.

Conflict of interest W. B. C. is President and owner of Athena Institute for Women's Wellness, Inc., manufacturer of the two synthesized pheromone products tested in the three double-blind studies. E. G. serves as an uncompensated advisor to the Institute from time to time.

Source of funding Athena Institute provided no funding to the San Francisco study; some funding to the Boston study; and all funding of the Philadelphia study but no compensation to the co-authors of the Philadelphia study who contributed their time from their own academic schedules at their separate universities.

References

15. Cutler WB, Davidson JM, McCoy N. Sexual behavior, steroids and hot flashes are associated during the perimenopause. Neuroendocrinology 1983;5:185
22. Burleson M, Gregory WL, Trevathan W. Heterosexual activity and cycle length variability: effect
49. Savic I, Berglund H, Gulyas, Roland P. Smelling of odorous sex hormone-like compounds causes sex-differentiated hypothalamic activations in humans. *Neuron* 2001;31:512–14